Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 8813138)

Published in Cancer Res on October 01, 1996

Authors

R Paus1, M B Schilli, B Handjiski, A Menrad, B M Henz, P Plonka

Author Affiliations

1: Department of Dermatology, Virchow Hospital, Humboldt-Universität zu Berlin, Germany. ralfpaus@ukrv.de

Articles citing this

Analysis of apoptosis during hair follicle regression (catagen) Am J Pathol (1997) 1.82

p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19

Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol (1997) 1.17

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16

Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer (2012) 1.02

Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol (2007) 0.92

A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer (2014) 0.87

Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs (2014) 0.86

Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia. BMC Pharmacol Toxicol (2013) 0.77

1α,25-dihydroxyvitamin D3 modulates the hair-inductive capacity of dermal papilla cells: therapeutic potential for hair regeneration. Stem Cells Transl Med (2012) 0.76

A study on the extracts of Cuscuta reflexa Roxb. in treatment of cyclophosphamide induced alopecia. Daru (2014) 0.75

Articles by these authors

A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol (2001) 6.12

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res (2000) 3.02

A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92

Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24

C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55

EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55

Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48

Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40

[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38

Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol (1994) 1.30

Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol (2000) 1.29

EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28

Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27

Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26

A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A. J Invest Dermatol (1994) 1.18

Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol (1997) 1.17

Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res (1999) 1.17

Indications for a 'brain-hair follicle axis (BHA)': inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. FASEB J (2001) 1.17

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13

Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09

Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res (2001) 1.09

Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06

Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04

Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03

Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01

A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res (1997) 0.99

Activated skin mast cells are involved in murine hair follicle regression (catagen). Lab Invest (1997) 0.98

Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97

Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97

Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97

Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96

Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95

Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94

Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94

Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94

Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93

Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93

Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92

Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91

Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91

Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91

Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91

Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood (1998) 0.90

Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90

Microscopic morphology of different types of urticaria. Arch Dermatol (1998) 0.90

Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc (2001) 0.89

Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol (1996) 0.89

Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (1996) 0.89

Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89

Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol (1998) 0.89

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol (2001) 0.88

Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood (1998) 0.88

Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res (1998) 0.88

Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. Br J Dermatol (2002) 0.87

Hair growth control by immunosuppression. Arch Dermatol Res (1996) 0.87

Detection of intracellular interleukin-8 in human mast cells: flow cytometry as a guide for immunoelectron microscopy. J Histochem Cytochem (1997) 0.87

Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. J Invest Dermatol (1996) 0.87

Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells. Scand J Immunol (1997) 0.87

Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol (2002) 0.87

The transcription factor profile of human mast cells in comparison with monocytes and granulocytes. Cell Mol Life Sci (2005) 0.87

Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol (1999) 0.86

Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86

Hair cycle-dependent changes in the gene expression and protein content of transforming factor beta 1 and beta 3 in murine skin. Arch Dermatol Res (1997) 0.86

Crossreacting IgG antibodies against fox mite antigens in human scabies. Arch Dermatol Res (2004) 0.85

Mastocytosis: review of clinical and experimental aspects. J Investig Dermatol Symp Proc (2001) 0.85

Overexpression of Bcl-2 protects from ultraviolet B-induced apoptosis but promotes hair follicle regression and chemotherapy-induced alopecia. Am J Pathol (2000) 0.85

GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. Arch Dermatol Res (2001) 0.84

Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol (1998) 0.84

Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol (2004) 0.84

Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor. Scand J Immunol (1999) 0.83

Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ (2006) 0.83

Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology (1998) 0.83

Regulation and possible function of axl expression in immature human mast cells. Ann Hematol (1998) 0.83

Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins. J Invest Dermatol (1996) 0.83

Neutrophilic urticaria: clinical features, histological changes and possible mechanisms. Br J Dermatol (1998) 0.83

Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer (2000) 0.83

AP-2 gene expression and modulation by retinoic acid during keratinocyte differentiation. Biochem Biophys Res Commun (1996) 0.83

Angiotensin II stimulates proliferation of primary human keratinocytes via a non-AT1, non-AT2 angiotensin receptor. Biochem Biophys Res Commun (1996) 0.83

Oral zinc sulphate causes murine hair hypopigmentation and is a potent inhibitor of eumelanogenesis in vivo. Br J Dermatol (2006) 0.82

High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol (1996) 0.82

A subclone (5C6) of the human mast cell line HMC-1 represents a more differentiated phenotype than the original cell line. Arch Dermatol Res (1996) 0.82

Expression of mast cell growth modulating and chemotactic factors and their receptors in human cutaneous scars. J Invest Dermatol (2001) 0.82

Phacomatosis pigmentokeratotica: a patient with the rare melanocytic-epidermal twin nevus syndrome. Dermatology (1997) 0.82

Retinoic acid inhibits CD40 plus IL-4 mediated IgE production through alterations of sCD23, sCD54 and IL-6 production. Inflamm Res (2005) 0.81

[Biology of the hair follicle]. Hautarzt (1994) 0.81

The mast cell products histamine and serotonin stimulate and TNF-alpha inhibits the proliferation of murine epidermal keratinocytes in situ. J Dermatol Sci (1997) 0.81

Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor. Biochem Biophys Res Commun (2000) 0.81

Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue. J Invest Dermatol (2000) 0.81

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCCD) affects keratin 1 and keratin 17 gene expression and differentially induces keratinization in hairless mouse skin. J Invest Dermatol (1997) 0.81

Progesterone withdrawal up-regulates vascular endothelial growth factor receptor type 2 in the superficial zone stroma of the human and macaque endometrium: potential relevance to menstruation. J Clin Endocrinol Metab (2000) 0.81

Expression of MC1- and MC5-receptors on the human mast cell line HMC-1. Ann N Y Acad Sci (1999) 0.81

Distribution and potential biologic function of the thrombin receptor PAR-1 on human keratinocytes. Arch Dermatol Res (2000) 0.80

Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells. Immunology (2000) 0.80

Anti-FcepsilonRIalpha serum autoantibodies in different subtypes of urticaria. Allergy (2000) 0.80